LIM domain kinases 1 and 2 (LIMK1 and LIMK2) regulate actin dynamics and subsequently key cellular functions such as proliferation and migration. LIMK1 and LIMK2 phosphorylate and inactivate cofilin leading to increased actin polymerization. As a result, LIMK inhibitors are emerging as a promising treatment strategy for certain cancers and neurological disorders. High-quality chemical probes are required if the role of these kinases in health and disease is to be understood. To that end, we report the results of a comparative assessment of 17 reported LIMK1/2 inhibitors in a variety of enzymatic and cellular assays. Our evaluation has identified three compounds (TH-257, LIJTF500025, and LIMKi3) as potent and selective inhibitors suitable for use as and pharmacological tools for the study of LIMK function in cell biology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619402PMC
http://dx.doi.org/10.1021/acs.jmedchem.2c00751DOI Listing

Publication Analysis

Top Keywords

limk1/2 inhibitors
8
limk1 limk2
8
comparative analysis
4
analysis small-molecule
4
small-molecule limk1/2
4
inhibitors
4
inhibitors chemical
4
chemical synthesis
4
synthesis biochemistry
4
biochemistry cellular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!